![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
The item has been added to your shopping cart.
Home » DAIICHI SPEEDS SUNTORY JV BUYOUT, RAISES FORECAST
DAIICHI SPEEDS SUNTORY JV BUYOUT, RAISES FORECAST
September 14, 2005
Japan's Daiichi Pharmaceutical Co. Ltd. said on Wednesday it moved up the buyout of its joint venture with Suntory to Sept. 15 from the previously scheduled October-March period and raised its full-year profit forecast because of an accounting change. Daiichi, Japan's fifth-biggest drug maker, now sees a net profit for the year through March 2006 of 30 billion yen ($271 million), up from its July estimate of 21 billion yen. Daiichi had originally planned to buy the 34 percent of Daiichi Suntory Pharma Co. Ltd. that it did not own by the end of March, but decided to advance the time frame ahead of Daiichi's merger with Sankyo Co. Ltd., set for Sept. 28.
Yahoo News (http://asia.news.yahoo.com/050914/3/27acw.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct